nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00005095,Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study,,Recruiting,Observational,"Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2); Ovarian Cancer; Sarcoma; Uterine Leiomyomata; Vaginal Cancer; Vulvar Cancer",Ca-125; screening questionnaire administration; Surgery,,Northwestern University,National Cancer Institute (NCI),6000,2000-03-05,2040-12-05,United States,No,https://clinicaltrials.gov/study/NCT00005095
NCT00823654,Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer BRCA Mutations,,Recruiting,Observational,Breast Cancer,Blood draw and questionnaires; Blood draw and questionnaires,,Memorial Sloan Kettering Cancer Center,Yale University; New York Presbyterian Hospital; Weill Medical College of Cornell University,609,2009-01-05,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT00823654
NCT01102569,Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients,,Recruiting,Observational,Pancreatic Cancer,,,Columbia University,,100,2008-01-05,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT01102569
NCT01174121,"A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab",Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors,Pembrolizumab (Keytruda); Fludarabine; Cyclophosphamide; Aldesleukin; Young TIL,,National Cancer Institute (NCI),,332,2010-08-26,2029-12-27,United States,No,https://clinicaltrials.gov/study/NCT01174121
NCT02000089,The Cancer of the Pancreas Screening-5 CAPS5)Study,Phase 3,Recruiting,Interventional,Pancreas Cancer; Peutz-Jeghers Syndrome (PJS); Gene Mutation; Germline Mutation Carrier; Lynch Syndrome,Secretin; MRI; Tumor marker gene test with CA19-9,,Johns Hopkins University,National Cancer Institute (NCI); National Institutes of Health (NIH); American Association for Cancer Research,9000,2014-01-06,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT02000089
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02288676,DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics,,Recruiting,Observational,Ovarian Neoplasms; Endometrial Neoplasms; Endometrial Cancer; Ovarian Cancer; Screening; Safety; Reduced Mortality; Reduced Morbidity; Early Diagnosis,,,McGill University,McGill University Health Centre/Research Institute of the McGill University Health Centre,1200,2014-01-05,2026-10-05,Canada,No,https://clinicaltrials.gov/study/NCT02288676
NCT02296307,Diagnosing Ovarian & Endometrial Cancer Early (DOvEE) by Targeting Symptomatic Women,,Recruiting,Observational,Ovarian Neoplasms,Blood test: CA-125 biomarker; Second Test: Transvaginal Ultrasound; Follow-up phone call,,McGill University,,13600,2012-01-05,2026-01-05,Canada,No,https://clinicaltrials.gov/study/NCT02296307
NCT02302742,"PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations",,Recruiting,Observational,Breast Cancer; Hereditary Breast and Ovarian Cancer,,,University of Kansas Medical Center,,1500,2011-03-22,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT02302742
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT02732860,Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host,,Recruiting,Observational,Colorectal Neoplasms; Colorectal Cancer; Breast Cancer; Breast Neoplasms; Ovarian Cancer; Ovarian Neoplasm,Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures,,"University Health Network, Toronto",,120,2015-12-05,2026-01-04,Canada,No,https://clinicaltrials.gov/study/NCT02732860
NCT02775461,Pancreas Disease and High Risk Registry,,Recruiting,Observational,Pancreas Cancer; Pancreatitis; Chronic Pancreatitis; Pancreatic Cyst; Family History of Pancreas Cancer; Genetic Mutations,,,Icahn School of Medicine at Mount Sinai,,1116,2013-03-01,2033-11-05,United States,No,https://clinicaltrials.gov/study/NCT02775461
NCT03419689,Biomarker Discovery Project in High Grade Serous Ovarian Cancer,Not Applicable,Recruiting,Interventional,Gynecologic Cancer,Tumour tissue collection; Blood sample collection; Ascites Collection; Fluid Collection,,"University Health Network, Toronto",,510,2018-01-08,2028-06-08,Canada,No,https://clinicaltrials.gov/study/NCT03419689
NCT03428802,A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability,Phase 2,Recruiting,Interventional,BRCA1 Gene Mutation; BRCA2 Gene Mutation; Locally Advanced Solid Neoplasm; Metastatic Malignant Solid Neoplasm; POLD1 Gene Mutation; POLE Gene Mutation; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Stage III Breast Cancer AJCC v7; Stage III Ovarian Cancer AJCC v8; Stage IIIA Breast Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIB Breast Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Breast Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8,Laboratory Biomarker Analysis; Pembrolizumab,,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI),40,2018-03-08,2023-10-02,United States,No,https://clinicaltrials.gov/study/NCT03428802
NCT03544983,A Randomized Trial of Proactive Outreach and Streamlined Genetic Education in BRCA Families,Not Applicable,Enrolling by invitation,Interventional,BRCA1 Mutation; BRCA2 Mutation,Web + Streamlined Telephone Genetic Information,,Georgetown University,George Washington University,240,2020-05-01,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT03544983
NCT03564340,"A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers",Phase 1/Phase 2,Recruiting,Interventional,Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Recurrent Primary Peritoneal Cancer; Recurrent Endometrial Cancer; Endometrial Cancer; Low-grade Serous Ovarian Cancer,Ubamatamab; Cemiplimab; Sarilumab; Tocilizumab,,Regeneron Pharmaceuticals,,890,2018-05-21,2027-01-31,Australia; Belgium; France; Israel; Italy; Netherlands; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT03564340
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03675893,"RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin, Zotatifin and Gedatolisib",Phase 2,Recruiting,Interventional,Endometrial Cancer; Ovarian Cancer,Letrozole; Abemaciclib; LY3023414; Metformin; Zotatifin; Gedatolisib,,Dana-Farber Cancer Institute,Eli Lilly and Company; Effector Therapeutics; Celcuity Inc,180,2018-12-24,2031-08-01,United States,No,https://clinicaltrials.gov/study/NCT03675893
NCT03702309,Liquid Biopsy Evaluation and Repository Development at Princess Margaret,,Recruiting,Observational,Cancer; Breast Cancer; Lung Cancer; Colon Cancer; Ovarian Cancer; Melanoma; Lymphoma; Leukemia; Mutation; Lynch Syndrome; Cowden Syndrome; BRCA1 Mutation; BRCA2 Mutation; Uterine Cancer; Myeloma; Kidney Cancer; Head and Neck Cancer; Meningioma,,,"University Health Network, Toronto",,2500,2017-08-03,2026-07-06,Canada,No,https://clinicaltrials.gov/study/NCT03702309
NCT03905941,Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age,Early Phase 1,Recruiting,Interventional,Polycystic Ovary Syndrome,Metformin; Oral combined hormonal contraceptives,,University of Virginia,,88,2021-08-23,2027-05-01,United States,No,https://clinicaltrials.gov/study/NCT03905941
NCT03943316,Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies,,Recruiting,Observational,Ovarian Cancer,,,New Mexico Cancer Research Alliance,,100,2015-12-02,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT03943316
NCT04065269,ATARI: ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss,Phase 2,Recruiting,Interventional,Gynaecological Cancers,Ceralasertib; Olaparib; Durvalumab,,"Institute of Cancer Research, United Kingdom",Cancer Research UK; AstraZeneca,174,2019-11-27,2026-04-05,Canada; United Kingdom,No,https://clinicaltrials.gov/study/NCT04065269
NCT04090567,Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer,Phase 2,Recruiting,Interventional,Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Germline BRCA1 Gene Mutation; Germline BRCA2 Gene Mutation; HER2/Neu Negative; Metastatic Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8,Cediranib; Ceralasertib; Olaparib,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),60,2020-07-28,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT04090567
NCT04196595,Apple Women's Health Study,,Recruiting,Observational,Menstrual Cycle; Ovulation; Menstruation; Polycystic Ovary Syndrome; Infertility; Menopause; Reproduction; Reproductive Health,,,Apple Inc.,Harvard School of Public Health (HSPH); National Institute of Environmental Health Sciences (NIEHS),500000,2019-11-14,2029-11-05,United States,No,https://clinicaltrials.gov/study/NCT04196595
NCT04251052,A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk],Not Applicable,Recruiting,Interventional,Ovarian Carcinoma,Bilateral Salpingectomy; Bilateral Salpingectomy with Oophorectomy; Biospecimen Collection; Magnetic Resonance Imaging; Quality-of-Life Assessment; Questionnaire Administration; Transvaginal Ultrasound; Ultrasound Imaging,,NRG Oncology,National Cancer Institute (NCI),1956,2020-09-01,2047-06-30,Canada; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04251052
NCT04294927,TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.,Not Applicable,Recruiting,Interventional,BRCA1 Gene Mutation; BRCA2 Gene Mutation; RAD51C Gene Mutation; RAD51D Gene Mutation; BRIP1 Gene Mutation; Ovarian Cancer,Risk-reducing salpingectomy with delayed oophorectomy; Risk-reducing salpingo-oophorectomy,,University Medical Center Nijmegen,,3000,2020-03-01,2040-02-17,Australia; Belgium; Brazil; Italy; Mexico; Netherlands; Norway; Poland; Sweden; United States; Uruguay,No,https://clinicaltrials.gov/study/NCT04294927
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04389632,A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Ovarian Neoplasms; Cutaneous Squamous Cell Cancer; Exocrine Pancreatic Adenocarcinoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Stomach Neoplasms",sigvotatug vedotin; pembrolizumab; cisplatin; carboplatin,,"Seagen, a wholly owned subsidiary of Pfizer",,1006,2020-06-08,2029-03-22,France; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04389632
NCT04431024,"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome",,Recruiting,Observational,Familial Cancer; BRCA1-Associated Protein-1 (BAP1) Mutations; Tumor Predisposition Syndrome (TPDS); Mesothelioma,,,National Cancer Institute (NCI),,800,2021-03-30,2038-06-30,United States,No,https://clinicaltrials.gov/study/NCT04431024
NCT04585958,A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies,Phase 1,Recruiting,Interventional,Metastatic Malignant Solid Neoplasm; Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma; Unresectable Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Multigated Acquisition Scan; Olaparib; Trastuzumab Deruxtecan,,National Cancer Institute (NCI),,55,2021-05-21,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04585958
NCT04633239,A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer,Phase 1,Recruiting,Interventional,Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma,Abemaciclib; Biopsy Procedure; Biospecimen Collection; Olaparib,,National Cancer Institute (NCI),,42,2021-07-02,2026-11-01,United States,No,https://clinicaltrials.gov/study/NCT04633239
NCT04657068,"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; Metastatic Colorectal Cancer; Pancreatic Ductal Adenocarcinoma; Acinar Cell Carcinoma,ART0380; Gemcitabine; Irinotecan,,Artios Pharma Ltd,,502,2020-12-13,2026-12-05,France; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04657068
NCT04794322,Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study,,Recruiting,Observational,Ovarian Neoplasms; Ovarian Epithelial Carcinoma; Fallopian Tube Neoplasms; High Grade Ovarian Serous Adenocarcinoma; Stage I Ovarian Cancer; Stage II Ovarian Cancer; Stage III Ovarian Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8,"Uterine lavage, or a wash of the womb; Blood sample; Pap smear",,Massachusetts General Hospital,Johns Hopkins University; Fred Hutchinson Cancer Center; Anne Arundel Health System Research Institute; University of Arkansas; National Cancer Institute (NCI); Kaiser Permanente; McGill University; M.D. Anderson Cancer Center; Swedish Medical Center; Early Detection Research Network,250,2020-04-13,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT04794322
NCT04847063,"Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies",Phase 1,Recruiting,Interventional,Peritoneal Carcinomatosis; Peritoneal Mesothelioma; Ovarian Cancer; Gastrointestinal Cancer; Appendiceal Cancer,Mitomycin C; Cisplatin; Heated Intraperitonial Chemotherapy; Doxorubicin; Oxaliplatin; 5-Fluorouracil; Sodium Thiosulfate,,National Cancer Institute (NCI),,60,2021-10-19,2031-12-30,United States,No,https://clinicaltrials.gov/study/NCT04847063
NCT04858334,"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation",Phase 2,Recruiting,Interventional,Pancreatic Acinar Cell Carcinoma; Pancreatic Adenosquamous Carcinoma; Pancreatic Squamous Cell Carcinoma; Resectable Pancreatic Acinar Cell Carcinoma; Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Placebo Administration,,National Cancer Institute (NCI),,152,2021-06-22,2027-10-31,Israel; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04858334
NCT04890613,Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation,Phase 1,Recruiting,Interventional,Advanced Solid Tumor,CX-5461,,"Senhwa Biosciences, Inc.",,52,2021-09-08,2026-12-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT04890613
NCT04918186,An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer,Phase 2,Recruiting,Interventional,Ovarian Cancer,Durvalumab; BA3011; BA3021; ENB003; Toripalimab,,Canadian Cancer Trials Group,"Cancer Research Institute, New York City; AstraZeneca; BioAtla, Inc.",60,2022-05-03,2026-12-31,Canada; United States,No,https://clinicaltrials.gov/study/NCT04918186
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05039801,"A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Endometrial Carcinoma; Advanced Head and Neck Squamous Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Melanoma; Advanced Ovarian Clear Cell Adenocarcinoma; Chondrosarcoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Ovarian High Grade Serous Adenocarcinoma; Refractory Endometrial Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma; Refractory Melanoma; Refractory Ovarian Clear Cell Adenocarcinoma; Refractory Ovarian High Grade Serous Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage III Uterine Corpus Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Uterine Corpus Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Uterine Corpus Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Uterine Corpus Cancer AJCC v8; Stage IIIC1 Uterine Corpus Cancer AJCC v8; Stage IIIC2 Uterine Corpus Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8,Bevacizumab; Glutaminase-1 Inhibitor IACS-6274; Paclitaxel; Capivasertib,,M.D. Anderson Cancer Center,,54,2021-09-09,2026-05-29,United States,No,https://clinicaltrials.gov/study/NCT05039801
NCT05065021,Re-VOLVE: A Phase II Clinical Trial in Women With Ovarian Cancer Progressing Post-PARP Inhibitor With Treatment Adapted to Real-time Assessment of Evolving Genomic Resistance,Phase 2,Recruiting,Interventional,Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High Grade Serous Cancer; High Grade Endometrioid Cancer,Niraparib; Dostarlimab; Bevacizumab; Paclitaxel,,"University Health Network, Toronto",GlaxoSmithKline,40,2023-02-23,2025-06-06,Canada,No,https://clinicaltrials.gov/study/NCT05065021
NCT05128825,"A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)",Phase 2,Recruiting,Interventional,"High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",azenosertib,,"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",,170,2022-02-17,2027-06-30,Australia; Belgium; France; Italy; Poland; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05128825
NCT05225428,Video Education With Result Dependent dIsclosure,Not Applicable,Recruiting,Interventional,Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma,Video Education; Genetic Counseling,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI),1020,2022-08-04,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05225428
NCT05227326,First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors,Phase 1,Recruiting,Interventional,Refractory Malignant Solid Neoplasm; Osteosarcoma; Leiomyosarcomas; Synovial Sarcomas; Ovarian Cancer; Non-Small Cell Lung Cancer; Pancreatic Cancer,PCNA Inhibitor AOH1996,,City of Hope Medical Center,National Cancer Institute (NCI),92,2022-08-12,2029-09-13,United States,No,https://clinicaltrials.gov/study/NCT05227326
NCT05281471,"A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma,"olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin (preferred) or cisplatin; Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin; Bevacizumab (or biosimilar)",,Genelux Corporation,GOG Foundation,186,2022-08-31,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT05281471
NCT05287451,Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study,Not Applicable,Recruiting,Interventional,Ovarian Cancer; Fallopian Tube Cancer,RIsk-Reducing Salpingectomy (RRS); Risk-Reducing Oophorectomy-RRO; Risk-Reducing Salpingo-Oophorectomy-RRSO,,M.D. Anderson Cancer Center,,100,2022-05-10,2026-12-26,United States,No,https://clinicaltrials.gov/study/NCT05287451
NCT05300711,"Preventing Ovarian Cancer Through the Expansion of Opportunistic Salpingectomy: Uptake, Safety and Cost-effectiveness at the Time of Colorectal Surgery",Not Applicable,Recruiting,Interventional,Salpingectomy; Colorectal Surgery,Bilateral salpingectomy; Colorectal surgery,,University of British Columbia,Canadian Cancer Society (CCS); Canadian Institutes of Health Research (CIHR),240,2022-06-20,2026-03-05,Canada,No,https://clinicaltrials.gov/study/NCT05300711
NCT05327010,"Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)",Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Diagnostic Imaging Testing; Talazoparib,,National Cancer Institute (NCI),,88,2022-11-14,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT05327010
NCT05366881,"cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse",,Recruiting,Observational,Brain Cancer; Breast Cancer; Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Esophageal Cancer; Stomach Cancer; Head and Neck Cancer; Hepatobiliary Cancer; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cancer; Sarcoma; Thyroid Cancer,,,"Adela, Inc",,7000,2022-05-03,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05366881
NCT05440617,Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy,,Recruiting,Observational,Acute Ovarian Failure; Infertility; Early Menopause And Infertility In Females After Treatment For Childhood Cancer,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,100,2022-07-22,2041-09-21,United States,No,https://clinicaltrials.gov/study/NCT05440617
NCT05512208,A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK),Phase 2,Recruiting,Interventional,Endometrioid Cancer; Mucinous Ovarian Cancer; High Grade Serous Ovarian Cancer; Cervical Cancer; Solid Tumor,Avutometinib (VS-6766) + defactinib,,University of Oklahoma,"Verastem, Inc.",55,2023-02-06,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT05512208
NCT05527184,"A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers",Phase 1,Recruiting,Interventional,Endometrial Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Cervical Cancer,IMGN151,,AbbVie,,423,2023-01-11,2027-02-05,Australia; Belgium; Canada; France; Germany; Ireland; Italy; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT05527184
NCT05554328,A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial,Phase 2,Recruiting,Interventional,Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma,Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Computed Tomography; Echocardiography Test; Multigated Acquisition Scan; Olaparib; Selumetinib Sulfate,,National Cancer Institute (NCI),NRG Oncology,165,2023-04-25,2028-10-01,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT05554328
NCT05579366,Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer,Rina-S; Carboplatin; Bevacizumab; Pembrolizumab,,Genmab,,764,2022-12-07,2027-10-05,China; Japan; United States,No,https://clinicaltrials.gov/study/NCT05579366
NCT05610735,"Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer",Phase 1/Phase 2,Recruiting,Interventional,Recurrent Ovarian Cancer,DOXIL; Withaferin A; Ashwagandha; Combination of ASWD and DOXIL,,Sham Sunder Kakar,University of Louisville Health Care,72,2024-09-25,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT05610735
NCT05625529,Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients,,Recruiting,Observational,Pancreas Cancer; Exosomes; Extracellular Vesicles; Pancreatic Neoplasms,,,Biological Dynamics,,1000,2022-12-19,2028-01-01,United States,No,https://clinicaltrials.gov/study/NCT05625529
NCT05636111,Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer,Phase 1,Recruiting,Interventional,Ovarian Cancer,Paclitaxel; Bevacizumab; Lurbinectedin,,M.D. Anderson Cancer Center,Jazz Pharmaceuticals,34,2023-07-12,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT05636111
NCT05649072,Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.,Not Applicable,Recruiting,Interventional,Ovarian Cancer; Breast Cancer; Colorectal Cancer,Genetic Testing and Counseling; Screening Form,,M.D. Anderson Cancer Center,Community Outreach and Engagement Fund for Underserved Texans,1000,2022-11-18,2027-02-02,United States,No,https://clinicaltrials.gov/study/NCT05649072
NCT05684965,"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,XTX301,,"Xilio Development, Inc.",,358,2023-05-11,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05684965
NCT05694715,Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; BRCA1 Mutation; BRCA2 Mutation; ATM Gene Mutation; PALB2 Gene Mutation,Niraparib; Irinotecan,,"University of California, San Francisco",GlaxoSmithKline,24,2023-05-23,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT05694715
NCT05787587,A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Endometrial Cancer; Colorectal Cancer; Head and Neck Cancers; Extensive Stage Small Cell Lung Cancer (ES-SCLC); NSCLC,IDE-161; Pembrolizumab,,IDEAYA Biosciences,Merck Sharp & Dohme LLC,216,2023-04-05,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT05787587
NCT05799274,Characterizing the Radiochemical and Radiation Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Ductal Adenocarcinoma or Other Solid Tumors,Phase 1,Recruiting,Interventional,Healthy Volunteers; Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Esophageal Squamous Cell Carcinoma; Cervical Cancer; Endometrial Cancer; Ovarian Cancer,RAD301 ([68Ga]-RAD301),,"Radiopharm Theranostics, Ltd",,9,2023-11-09,2025-11-05,United States,No,https://clinicaltrials.gov/study/NCT05799274
NCT05819853,Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome,Phase 3,Recruiting,Interventional,PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries; Obese,Semaglutide Injectable Product (Wegovy and/or Ozempic),,"University of Colorado, Denver",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),80,2023-11-03,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT05819853
NCT05827614,"An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications",Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer (TNBC); High Grade Serous Ovarian Carcinoma; High Grade Endometrial Carcinoma; Anogenital Cancer; Head and Neck (HNSCC); Cutaneous Squamous Cell Carcinoma (CSCC); Cervical Squamous Cell Carcinoma; ER+ Breast Cancer; Leiomyosarcoma (LMS); Undifferentiated Pleomorphic Sarcoma (UPS); Pancreatic Cancer Metastatic; Small Cell Lung Cancer,BBI-355; Erlotinib; Futibatinib; BBI-825,,Boundless Bio,,127,2023-03-24,2027-03-31,United States,No,https://clinicaltrials.gov/study/NCT05827614
NCT05902988,A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer,Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer; Triple Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Ovarian Carcinosarcoma; Uterine Carcinosarcoma; Uterine Serous Carcinoma; Endometrium Cancer; Chromosomal Instability,VLS-1488,,"Volastra Therapeutics, Inc.",,200,2023-10-18,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05902988
NCT05910294,Randomized Pilot Prevention Trial to Improve Sexual and Vulvovaginal Health Concerns in Premenopausal Female Breast Cancer Patients Receiving Ovarian Suppression,Not Applicable,Recruiting,Interventional,Improve Sexual Health; Improve Vulvovaginal Health,questionnaires; moisturizers; moisturizers,,Memorial Sloan Kettering Cancer Center,,50,2023-06-01,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT05910294
NCT05920798,"MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)",Phase 1/Phase 2,Recruiting,Interventional,Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube High Grade Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Carcinosarcoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma; Recurrent Primary Peritoneal Carcinosarcoma,Biopsy; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine; Pembrolizumab; Pheresis,,Mayo Clinic,NanoPass Technologies Ltd; National Cancer Institute (NCI),40,2023-09-28,2027-07-15,United States,No,https://clinicaltrials.gov/study/NCT05920798
NCT05950464,A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer,Phase 1,Recruiting,Interventional,Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian High Grade Serous Adenocarcinoma; Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Computed Tomography; Electrocardiography; Magnetic Resonance Imaging; Tuvusertib; X-Ray Imaging,,National Cancer Institute (NCI),NRG Oncology,60,2023-12-18,2026-04-30,United States,No,https://clinicaltrials.gov/study/NCT05950464
NCT05961124,"A Phase II, Single-Arm Trial Assessing Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer: Dose Escalation",Phase 2,Recruiting,Interventional,Ovarian Cancer; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; High Grade Ovarian Serous Adenocarcinoma,Niraparib,,Sunnybrook Health Sciences Centre,GlaxoSmithKline,40,2023-08-21,2027-09-05,Canada,No,https://clinicaltrials.gov/study/NCT05961124
NCT05985655,"A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Breast Carcinoma; High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC); Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma",GTAEXS617; SoC,,"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",,165,2023-07-06,2028-05-05,Belgium; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05985655
NCT05998135,Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer,Phase 2,Recruiting,Interventional,Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Ovarian Carcinoma,Atovaquone; Biopsy; Computed Tomography; Paracentesis,,Emory University,National Cancer Institute (NCI),28,2023-11-09,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT05998135
NCT06151223,A Prospective Registry for Patients at High-Risk for Pancreatic Cancer,,Recruiting,Observational,Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma,Bio-specimen Collection: Blood; Bio-specimen Collection: Pancreatic Juice; MRI,,Mayo Clinic,,5000,2021-07-13,2031-07-31,United States,No,https://clinicaltrials.gov/study/NCT06151223
NCT06177171,A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors,Phase 1,Recruiting,Interventional,BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; PALB2 Gene Mutation; Checkpoint Kinase 2 Gene Mutation; ATM Gene Mutation,Olaparib; ASTX727,,Pamela Munster,National Cancer Institute (NCI),18,2024-02-07,2027-02-28,United States,No,https://clinicaltrials.gov/study/NCT06177171
NCT06188520,"A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC),AZD8421; Camizestrant; Ribociclib; Palbociclib; Abemaciclib,,AstraZeneca,,348,2023-12-05,2026-06-17,Australia; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06188520
NCT06234423,"A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Ovarian Cancer; Solid Tumor,CUSP06,,"OnCusp Therapeutics, Inc.",,263,2024-02-09,2027-10-31,United States,No,https://clinicaltrials.gov/study/NCT06234423
NCT06268665,A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy,Phase 2,Recruiting,Interventional,"Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IV; Invasive Breast Cancer; Ovarian Cancer; Ovarian Cancer Stage 1; Ovarian Cancer Stage II; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Ovarian Cancer Stage IA; Ovarian Cancer Stage IB; Ovarian Cancer Stage IC; Ovarian Cancer Stage 2; Ovarian Cancer Stage 3; Ovarian Cancer Stage IIIb; Ovarian Cancer Stage IIIC; Breast Cancer Stage IIIA; Breast Cancer Invasive; Breast Cancer, Stage IA; Breast Cancer, Stage IB; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Cancer, Breast; Tumors, Breast; Mammary Cancer; Mammary Carcinoma; Breast Carcinoma; Breast Neoplasm; Malignant Breast Neoplasm; Malignant Tumor of Breast; Cancer of Ovary; Ovary Cancer; Ovary Neoplasm",Tart Cherry Juice,,Eve Rodler,,86,2024-08-15,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06268665
NCT06290193,A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer,Phase 2,Recruiting,Interventional,Ovarian Cancer; Fallopian Tube Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Ovarian Cancer Stage IIIC; Fallopian Tube Cancer Stage IIIC; Ovarian Cancer Stage IV; Fallopian Tube Cancer Stage IV; Fallopian Tube Cancer; Peritoneal Cancer,Acute Normovolemic Hemodilution/ANH,,Memorial Sloan Kettering Cancer Center,,86,2024-02-23,2029-02-23,United States,No,https://clinicaltrials.gov/study/NCT06290193
NCT06297525,"An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer",Phase 1,Recruiting,Interventional,Solid Tumor,STP938,,"Step Pharma, SAS",,70,2024-08-02,2027-05-05,France; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06297525
NCT06365853,A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression,Phase 2,Recruiting,Interventional,Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive,Mirvetuximab Soravtansine; Lubricating Eye Drops; Prednisolone acetate ophthalmic suspension 1% eye drops; Brimonidine tartrate ophthalmic solution eye drops,,AbbVie,,100,2024-07-29,2027-06-05,Australia; Belgium; Canada; France; Ireland; Spain; United States,No,https://clinicaltrials.gov/study/NCT06365853
NCT06376604,Use of a Fasting Mimicking Diet in Patients Undergoing Chemotherapy for Gynecologic Malignancies,Not Applicable,Recruiting,Interventional,"Cancer, Ovarian; Chemotherapy Effect; Calorie Deficiency; Fasting, Intermittent",Fasting Mimicking Diet; Chemotherapy,,L-Nutra Inc,University of Tennessee Medical Center,30,2021-09-08,2025-12-30,United States,No,https://clinicaltrials.gov/study/NCT06376604
NCT06395519,A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies,Phase 1/Phase 2,Recruiting,Interventional,Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarian Cancer; BRCA2 Mutation; ER+ Breast Cancer; Castrate Resistant Prostate Cancer; BRCA1 Mutation; BRCA Mutation; Endometrial Cancer; Colorectal Cancer; Gastric Cancer,ETX-19477,,"858 Therapeutics, Inc.",,120,2024-05-13,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06395519
NCT06451497,"Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer; Esophageal Cancer; Head and Neck Squamous Cell Carcinoma; Pancreas Adenocarcinoma; Biliary Tract Cancer; Prostate Cancer; Urothelial Carcinoma; Colorectal Cancer; Triple Negative Breast Cancer; High Grade Ovarian Serous Adenocarcinoma; Diffuse Large B Cell Lymphoma,ZM008,,Zumutor Biologics Inc.,,33,2024-05-22,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT06451497
NCT06476808,A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors,Phase 1,Recruiting,Interventional,High-grade Serous Ovarian Carcinoma (HGSOC); Uterine Serous Carcinoma (USC); Non-small Cell Lung Cancer (NSCLC),BMS-986463,,Bristol-Myers Squibb,,240,2024-09-06,2028-12-19,Canada; France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06476808
NCT06504147,"A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal Α-emitting Radionuclide Therapy (Radspherin®) in Patients with Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, with Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery",Phase 2,Recruiting,Interventional,Peritoneal Carcinomatosis; Ovarian Cancer,Radspherin,,Oncoinvent AS,,114,2024-06-15,2031-02-28,Belgium; Norway; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06504147
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06580314,"A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy",Phase 3,Recruiting,Interventional,Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma,Bevacizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib,,NRG Oncology,National Cancer Institute (NCI),880,2025-03-12,2034-12-31,Japan; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06580314
NCT06583395,Effects Of Meditation On The Gut Microbiome And Human Health and Disease,,Enrolling by invitation,Observational,"Amyotrophic Lateral Sclerosis (ALS); Angina, Stable; Anxiety; Asthma; Atrial Fibrillation; Cancer Brain; Cancer, Breast; Cancer Colon; Cancer, Lung; Cancer, Ovarian; Cancer Prostate; Cancer Skin; Throat Cancer; Lymphoma; Cancer, Thyroid; Cancer, Other; Cerebral Palsy; Chronic Fatigue Syndrome; Cluster Headache; Chronic Obstructive Pulmonary Disease (COPD); Chronic Kidney Diseases; Crohn Disease; Deafness; Depression; Diabetes; Eczema; Epilepsy; Fibroids; Fibromyalgia; Heart Failure; Hypertension; Hyperthyroidism; Hypothyroidism; Irritable Bowel Syndrome (IBS); Infertility; Lyme Disease; Macular Degeneration; Migraine; Multiple Allergies; Multiple Sclerosis; Osteoarthritis; Osteoporosis; Ovarian Cysts; Parkinson Disease; Phantom Limb Pain; Psoriasis; Post Traumatic Stress Disorder (PTSD); Rheumatoid Arthritis; Sjogrens Disease; Spinal Cord Injury; Spinal Stenosis; Stroke; Tension Headache; Tinnitus; Ulcerative Colitis",Advanced multi-component meditation practice,,Tobias Moeller-Bertram,"Metamorphosis, LLC; University of California, San Diego",3000,2021-12-05,2025-03-25,United States,No,https://clinicaltrials.gov/study/NCT06583395
NCT06619236,"A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer",Phase 3,Recruiting,Interventional,Platinum-resistant Ovarian Cancer,Rina-S; Paclitaxel; Topotecan; Pegylated liposomal doxorubicin (PLD); Gemcitabine,,Genmab,,530,2025-02-07,2028-05-23,Australia; Austria; Belgium; Canada; Czechia; Denmark; France; Germany; Greece; Italy; Japan; Netherlands; Norway; Poland; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06619236
NCT06630325,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT),Phase 2,Recruiting,Interventional,Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8,Abemaciclib; Biopsy; Bone Scan; Carboplatin; Echocardiography; Exemestane; Fulvestrant; Gefitinib; Gemcitabine; Letrozole; Multigated Acquisition Scan; Olaparib; Osimertinib; Paclitaxel; Pegylated Liposomal Doxorubicin Hydrochloride; Pemetrexed; Survey Administration; Tamoxifen; Temozolomide; Biospecimen Collection,,OHSU Knight Cancer Institute,Oregon Health and Science University; Eli Lilly and Company; AstraZeneca,30,2025-06-24,2033-06-30,United States,No,https://clinicaltrials.gov/study/NCT06630325
NCT06639074,MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT),Phase 2,Recruiting,Interventional,Advanced Fallopian Tube Carcinoma; Advanced Fallopian Tube High Grade Serous Adenocarcinoma; Advanced Ovarian Carcinoma; Advanced Ovarian Carcinosarcoma; Advanced Ovarian Clear Cell Adenocarcinoma; Advanced Ovarian Endometrioid Adenocarcinoma; Advanced Ovarian High Grade Serous Adenocarcinoma; Advanced Primary Peritoneal Carcinoma; Advanced Primary Peritoneal High Grade Serous Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Mixed Cell Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Clear Cell Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma,Biopsy; Biospecimen Collection; Computed Tomography; Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Leukapheresis; Magnetic Resonance Imaging; Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine; Placebo Administration; Tetanus and Diphtheria Toxoids Adsorbed,,Mayo Clinic,,78,2024-11-08,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06639074
NCT06654050,Phase II Study of Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma,Phase 2,Not yet recruiting,Interventional,Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma; Subclinical Mesothelioma; BRCA1-Associated Protein-1 (BAP1) Mutations; Early-stage BAP1-associated Malignancies,alrizomadlin,,National Cancer Institute (NCI),,15,2026-01-08,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT06654050
NCT06660654,"REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors",Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Solid Tumors,Raludotatug deruxtecan,,Daiichi Sankyo,Merck Sharp & Dohme LLC,200,2025-01-06,2027-09-30,Belgium; China; Denmark; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06660654
NCT06677190,A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary or Clear Cell Carcinoma of Other Gynecologic Origin,Phase 2,Recruiting,Interventional,Ovarian Cancer; Ovarian Carcinoma; Endometrial Cancer; Uterine Cancer; Cervical Cancer; Vulvar Cancer; Gynecologic Cancer; Vaginal Cancer,Belzutifan,,Dana-Farber Cancer Institute,Merck Sharp & Dohme LLC,32,2024-12-20,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06677190
NCT06732336,HER2-PET Imaging Using 89Zr-trastuzumab in Low HER2-expressing (HER2-low) Breast Cancers,Phase 1/Phase 2,Recruiting,Interventional,Breast Cancer Metastatic,89Zr-trastuzumab,,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Université de Sherbrooke,40,2024-12-01,2026-03-31,Canada,No,https://clinicaltrials.gov/study/NCT06732336
NCT06760507,Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics,Not Applicable,Recruiting,Interventional,Breast Cancer; Ovarian Cancer,Adapted Family History Screening Program,,Emory University,National Cancer Institute (NCI),3209,2025-02-01,2028-06-30,United States,No,https://clinicaltrials.gov/study/NCT06760507
NCT06799065,"A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer",Phase 1,Recruiting,Interventional,Advanced Solid Tumors; Breast Cancer Recurrent; Ovarian Cancer; High-grade Serous Ovarian Carcinoma; Triple Negative Breast Cancer,ATX-295,,Accent Therapeutics,,90,2025-03-21,2027-08-30,United States,No,https://clinicaltrials.gov/study/NCT06799065
NCT06843447,"A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy",Phase 1/Phase 2,Recruiting,Interventional,Ovarian Cancer Recurrent,Raludotatug Deruxtecan; Carboplatin; Paclitaxel; Bevacizumab; Rescue Medication; Pembrolizumab,,Merck Sharp & Dohme LLC,Daiichi Sankyo,280,2025-04-15,2029-03-27,Israel; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06843447
NCT06892275,The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI,Not Applicable,Recruiting,Interventional,Breast Neoplasm Female; Early Detection of Cancer; Hereditary Breast and Ovarian Cancer Syndrome; Magnetic Resonance Imaging,Enhanced Usual Care; Decision Support,,Georgetown University,,80,2025-06-01,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06892275
NCT06910657,"A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors,IDOV-Immune (oncolytic vaccinia virus),,"ViroMissile, Inc.",,78,2025-08-25,2027-05-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT06910657
NCT06971744,Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial,Phase 2,Recruiting,Interventional,Ovarian Cancer,Hydroxychloroquine; Nelfinavir; Bevacizumab,,Medical University of South Carolina,,38,2025-12-18,2029-06-18,United States,No,https://clinicaltrials.gov/study/NCT06971744
